Litcius/Paper detail

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal, Basem M. William, Javier Muñoz, Gilles Salles, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Ibrahim Yakoub‐Agha, Olalekan O. Oluwole, Henry C. Fung, Joseph D. Rosenblatt, John M. Rossi, Lovely Goyal, Vicki Plaks, Yin Yang, Remus Vezan, Mauro P. Avanzi, Sattva S. Neelapu

2021The Lancet Oncology617 citationsDOI

Topics & Concepts

MedicineFollicular lymphomaInternal medicineLymphomaFludarabineOncologyPopulationGastroenterologySurgeryCyclophosphamideChemotherapyEnvironmental healthCAR-T cell therapy researchLymphoma Diagnosis and TreatmentImmune Cell Function and Interaction